Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation

M. Hasib Sidiqi, Mohammed A. Aljama, Dragan Jevremovic, William G. Morice, Michael Timm, Francis K. Buadi, Rahma Warsame, Martha Lacy, Angela Dispenzieri, David M Dingli, Wilson Gonsalves, Shaji K Kumar, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, William Hogan, Morie Gertz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The plasma cell proliferative index provides an insight into plasma cell biology in plasma cell disorders and is an important prognostic marker in myeloma and smoldering myeloma. We analyzed the prognostic impact of the plasma cell proliferative index in 513 patients with systemic immunoglobulin light chain (AL) amyloidosis undergoing stem cell transplantation at the Mayo Clinic between 1st January 2003 and 31st August 2016. Two cohorts were identified according to Low or Elevated plasma cell proliferative index. Patients with an Elevated plasma cell proliferative index had more cardiac involvement (56% vs. 44%; P=0.01), less renal involvement (55% vs. 70%; P=0.001), and were more likely to have 10% or over bone marrow plasma cells (58% vs. 32%; P<0.0001) compared to those with a Low plasma cell proliferative index. Both progression-free survival and overall survival were lower in patients with an Elevated compared to Low plasma cell proliferative index: median progression-free survival 44 vs. 95 months (P<0.0001) and median overall survival 102 vs. 143 months (P=0.0003). All-cause mortality at 100 days was higher in patients with an Elevated plasma cell proliferative index (elevated 10.3% vs. low 4.3%; P=0.008). On multivariate analysis Elevated plasma cell proliferative index was an independent prognostic factor for overall survival (Hazard Ratio 1.5, 95%CI: 1.1-2.1; P=0.021). The plasma cell proliferative index is an important prognostic tool in patients with AL amyloidosis undergoing stem cell transplant.

Original languageEnglish (US)
Pages (from-to)1229-1234
Number of pages6
JournalHaematologica
Volume103
Issue number7
DOIs
StatePublished - Jul 3 2018

Fingerprint

Immunoglobulin Light Chains
Stem Cell Transplantation
Amyloidosis
Plasma Cells
Disease-Free Survival
Survival
Bone Marrow Cells
Cell Biology

ASJC Scopus subject areas

  • Hematology

Cite this

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. / Sidiqi, M. Hasib; Aljama, Mohammed A.; Jevremovic, Dragan; Morice, William G.; Timm, Michael; Buadi, Francis K.; Warsame, Rahma; Lacy, Martha; Dispenzieri, Angela; Dingli, David M; Gonsalves, Wilson; Kumar, Shaji K; Kapoor, Prashant; Kourelis, Taxiarchis; Leung, Nelson; Hogan, William; Gertz, Morie.

In: Haematologica, Vol. 103, No. 7, 03.07.2018, p. 1229-1234.

Research output: Contribution to journalArticle

@article{7c81a711671743b78e820dd1d686dd02,
title = "Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation",
abstract = "The plasma cell proliferative index provides an insight into plasma cell biology in plasma cell disorders and is an important prognostic marker in myeloma and smoldering myeloma. We analyzed the prognostic impact of the plasma cell proliferative index in 513 patients with systemic immunoglobulin light chain (AL) amyloidosis undergoing stem cell transplantation at the Mayo Clinic between 1st January 2003 and 31st August 2016. Two cohorts were identified according to Low or Elevated plasma cell proliferative index. Patients with an Elevated plasma cell proliferative index had more cardiac involvement (56{\%} vs. 44{\%}; P=0.01), less renal involvement (55{\%} vs. 70{\%}; P=0.001), and were more likely to have 10{\%} or over bone marrow plasma cells (58{\%} vs. 32{\%}; P<0.0001) compared to those with a Low plasma cell proliferative index. Both progression-free survival and overall survival were lower in patients with an Elevated compared to Low plasma cell proliferative index: median progression-free survival 44 vs. 95 months (P<0.0001) and median overall survival 102 vs. 143 months (P=0.0003). All-cause mortality at 100 days was higher in patients with an Elevated plasma cell proliferative index (elevated 10.3{\%} vs. low 4.3{\%}; P=0.008). On multivariate analysis Elevated plasma cell proliferative index was an independent prognostic factor for overall survival (Hazard Ratio 1.5, 95{\%}CI: 1.1-2.1; P=0.021). The plasma cell proliferative index is an important prognostic tool in patients with AL amyloidosis undergoing stem cell transplant.",
author = "Sidiqi, {M. Hasib} and Aljama, {Mohammed A.} and Dragan Jevremovic and Morice, {William G.} and Michael Timm and Buadi, {Francis K.} and Rahma Warsame and Martha Lacy and Angela Dispenzieri and Dingli, {David M} and Wilson Gonsalves and Kumar, {Shaji K} and Prashant Kapoor and Taxiarchis Kourelis and Nelson Leung and William Hogan and Morie Gertz",
year = "2018",
month = "7",
day = "3",
doi = "10.3324/haematol.2018.189985",
language = "English (US)",
volume = "103",
pages = "1229--1234",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

TY - JOUR

T1 - Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation

AU - Sidiqi, M. Hasib

AU - Aljama, Mohammed A.

AU - Jevremovic, Dragan

AU - Morice, William G.

AU - Timm, Michael

AU - Buadi, Francis K.

AU - Warsame, Rahma

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Dingli, David M

AU - Gonsalves, Wilson

AU - Kumar, Shaji K

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis

AU - Leung, Nelson

AU - Hogan, William

AU - Gertz, Morie

PY - 2018/7/3

Y1 - 2018/7/3

N2 - The plasma cell proliferative index provides an insight into plasma cell biology in plasma cell disorders and is an important prognostic marker in myeloma and smoldering myeloma. We analyzed the prognostic impact of the plasma cell proliferative index in 513 patients with systemic immunoglobulin light chain (AL) amyloidosis undergoing stem cell transplantation at the Mayo Clinic between 1st January 2003 and 31st August 2016. Two cohorts were identified according to Low or Elevated plasma cell proliferative index. Patients with an Elevated plasma cell proliferative index had more cardiac involvement (56% vs. 44%; P=0.01), less renal involvement (55% vs. 70%; P=0.001), and were more likely to have 10% or over bone marrow plasma cells (58% vs. 32%; P<0.0001) compared to those with a Low plasma cell proliferative index. Both progression-free survival and overall survival were lower in patients with an Elevated compared to Low plasma cell proliferative index: median progression-free survival 44 vs. 95 months (P<0.0001) and median overall survival 102 vs. 143 months (P=0.0003). All-cause mortality at 100 days was higher in patients with an Elevated plasma cell proliferative index (elevated 10.3% vs. low 4.3%; P=0.008). On multivariate analysis Elevated plasma cell proliferative index was an independent prognostic factor for overall survival (Hazard Ratio 1.5, 95%CI: 1.1-2.1; P=0.021). The plasma cell proliferative index is an important prognostic tool in patients with AL amyloidosis undergoing stem cell transplant.

AB - The plasma cell proliferative index provides an insight into plasma cell biology in plasma cell disorders and is an important prognostic marker in myeloma and smoldering myeloma. We analyzed the prognostic impact of the plasma cell proliferative index in 513 patients with systemic immunoglobulin light chain (AL) amyloidosis undergoing stem cell transplantation at the Mayo Clinic between 1st January 2003 and 31st August 2016. Two cohorts were identified according to Low or Elevated plasma cell proliferative index. Patients with an Elevated plasma cell proliferative index had more cardiac involvement (56% vs. 44%; P=0.01), less renal involvement (55% vs. 70%; P=0.001), and were more likely to have 10% or over bone marrow plasma cells (58% vs. 32%; P<0.0001) compared to those with a Low plasma cell proliferative index. Both progression-free survival and overall survival were lower in patients with an Elevated compared to Low plasma cell proliferative index: median progression-free survival 44 vs. 95 months (P<0.0001) and median overall survival 102 vs. 143 months (P=0.0003). All-cause mortality at 100 days was higher in patients with an Elevated plasma cell proliferative index (elevated 10.3% vs. low 4.3%; P=0.008). On multivariate analysis Elevated plasma cell proliferative index was an independent prognostic factor for overall survival (Hazard Ratio 1.5, 95%CI: 1.1-2.1; P=0.021). The plasma cell proliferative index is an important prognostic tool in patients with AL amyloidosis undergoing stem cell transplant.

UR - http://www.scopus.com/inward/record.url?scp=85049570913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049570913&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.189985

DO - 10.3324/haematol.2018.189985

M3 - Article

C2 - 29674497

AN - SCOPUS:85049570913

VL - 103

SP - 1229

EP - 1234

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -